Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARY DENISE HUGHES

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1275643561
CMS profile
329730
Location
GREENVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$64,942.85

121 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARY DENISE HUGHES

NPI 1275643561 · CMS profile ID 329730

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

GREENVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275643561?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARY DENISE HUGHES, NPI 1275643561, CMS profile ID 329730. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275643561?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MARY DENISE HUGHES, NPI 1275643561, CMS profile ID 329730. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275643561?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MARY DENISE HUGHES, NPI 1275643561, CMS profile ID 329730, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1275643561?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

121 matching records · $64,942.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 121 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–121 of 121.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $43.9503/16/2022 Grant No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061281172 CMS
Lilly USA, LLC $43.9503/16/2022 Grant No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918182757 CMS
EMD Serono, Inc. $48.7803/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941497725 CMS
EMD Serono, Inc. $67.0703/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941497729 CMS
EMD Serono, Inc. $49.3903/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941498051 CMS
EMD Serono, Inc. $49.3903/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941498055 CMS
EMD Serono, Inc. $203.5403/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941497089 CMS
EMD Serono, Inc. $14.6303/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941497093 CMS
EMD Serono, Inc. $37.9503/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941497097 CMS
EMD Serono, Inc. $7.6103/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941497099 CMS
EMD Serono, Inc. $126.2503/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941497103 CMS
Teva Pharmaceuticals USA, Inc. $11.5602/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954532751 CMS
EMD Serono, Inc. $14.3202/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941492957 CMS
Horizon Therapeutics plc $3.1001/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937635533 CMS
Celgene Corporation $8.0001/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932724527 CMS
Teva Pharmaceuticals USA, Inc. $4.0001/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954532683 CMS
EMD Serono, Inc. $12.6401/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941486983 CMS
EMD Serono, Inc. $3.5901/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941487271 CMS
Horizon Therapeutics plc $12.8301/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937635531 CMS
Celgene Corporation $3.0701/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932724525 CMS
Teva Pharmaceuticals USA, Inc. $4.9701/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954532679 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $135,973.92 222
PY2020 $50,537.80 81
PY2021 $28,471.17 68
PY2022 $64,942.85 121
PY2023 $62,056.98 121
PY2024 $48,792.79 153
PY2025 $13,219.68 129

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $124.67 2
PY2025 Principal investigator $873,707.70 120
PY2024 Recipient $2,475.64 15
PY2024 Principal investigator $856,148.84 102
PY2023 Recipient $2,733.96 2
PY2023 Principal investigator $989,172.06 137
PY2022 Recipient $424.00 1
PY2022 Principal investigator $1,107,607.95 91
PY2021 Recipient $195.16 1
PY2021 Principal investigator $779,515.43 65
PY2020 Recipient $11,016.00 1
PY2020 Principal investigator $526,767.78 30
PY2019 Principal investigator $771,057.05 69

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

122 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202534679
Principal investigator 1 Novartis Pharmaceuticals Corporation $51,500.00 12/17/2025 Non-covered Recipient Entity
LIFESTYLE NEUROLOGY, LLC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190308818
Principal investigator 1 Roche Products Limited $1,000.00 12/10/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617171
Principal investigator 1 TG Therapeutics, Inc. $6,628.49 12/09/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199075
Principal investigator 1 ABBVIE INC. $8,227.80 12/04/2025 Non-covered Recipient Entity
PREMIER NEUROLOGY PC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202527788
Principal investigator 1 EMD Serono, Inc. $2,500.00 11/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118403
Principal investigator 1 EMD Serono, Inc. $2,500.00 11/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118406
Principal investigator 1 ABBVIE INC. $3,329.20 11/05/2025 Non-covered Recipient Entity
PREMIER NEUROLOGY PC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522141
Principal investigator 1 TG Therapeutics, Inc. $16,495.54 11/01/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199073
Principal investigator 1 ABBVIE INC. $9,839.34 10/30/2025 Non-covered Recipient Entity
INTERSPOND LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202519881
Principal investigator 1 ABBVIE INC. $8,863.40 10/09/2025 Non-covered Recipient Entity
PREMIER NEUROLOGY PC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202515163
Principal investigator 1 TG Therapeutics, Inc. $1,067.44 10/07/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199065
Principal investigator 1 Amgen Inc. $21,500.00 10/03/2025 Non-covered Recipient Entity
PREMIER NEUROLOGY PC
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis No dispute reported 06/30/2026 1246646739
Principal investigator 1 TG Therapeutics, Inc. $23,124.03 09/30/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199025
Recipient Novartis Pharma AG $76.67 09/24/2025 Covered Recipient Physician CLOU064C12301, CLOU064C12302 No dispute reported 06/30/2026 1248109407
Principal investigator 1 Roche Products Limited $544.03 09/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617157
Principal investigator 1 Roche Products Limited $544.03 09/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617165
Principal investigator 1 GENZYME CORPORATION $61,211.00 09/15/2025 Non-covered Recipient Entity
Interspond LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226148231
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,333.82 09/01/2025 Non-covered Recipient Entity
PREMIER NEUROLOGY
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190305543
Principal investigator 1 TG Therapeutics, Inc. $23,215.91 08/31/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199023
Principal investigator 1 GENZYME CORPORATION $1,860.00 08/25/2025 Non-covered Recipient Entity
Interspond LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226148227
Principal investigator 1 Roche Products Limited $544.03 08/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617149
Principal investigator 1 Roche Products Limited $544.03 08/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617161
Principal investigator 1 Roche Products Limited $5.30 08/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617169
Principal investigator 1 EMD Serono, Inc. $500.00 08/01/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118399
Principal investigator 1 TG Therapeutics, Inc. $6,575.34 07/31/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199021
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 07/14/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199059
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 07/07/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199057
Principal investigator 1 ABBVIE INC. $9,913.40 07/02/2025 Non-covered Recipient Entity
PREMIER NEUROLOGY PC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202496485
Principal investigator 1 Genentech, Inc. $15,341.00 07/01/2025 Non-covered Recipient Entity
INTERSPOND LLC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211617275
Principal investigator 1 EMD Serono, Inc. $561.00 06/19/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118392
Principal investigator 1 EMD Serono, Inc. $561.00 06/19/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118396
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616939
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616946
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616955
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616958
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616962
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616966
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616970
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616985
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616992
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616997
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617009
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617013
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617022
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617025
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617029
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617032
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617047
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617050
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617055
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617059
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617070
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617074
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617079
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617094
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617101
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617105
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617108
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617112
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617125
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617133
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617142
Principal investigator 1 Roche Products Limited $544.03 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617145
Principal investigator 1 ABBVIE INC. $4,946.20 06/03/2025 Non-covered Recipient Entity
PREMIER NEUROLOGY PC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202488089
Principal investigator 1 TG Therapeutics, Inc. $8,453.00 06/01/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198959
Principal investigator 1 GENZYME CORPORATION $7,500.00 05/19/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148036
Principal investigator 1 GENZYME CORPORATION $9,459.00 05/19/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226148041
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616928
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616932
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616937
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616943
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616951
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616974
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616977
Principal investigator 1 Roche Products Limited $439.86 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616981
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211616988
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617000
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617005
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617035
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617039
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617043
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617063
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617067
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617085
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617090
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617097
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617128
Principal investigator 1 Roche Products Limited $544.03 05/16/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211617137
Principal investigator 1 ABBVIE INC. $18,461.80 05/07/2025 Non-covered Recipient Entity
PREMIER NEUROLOGY PC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202483807
Principal investigator 1 EMD Serono, Inc. $500.00 05/05/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118388
Principal investigator 1 Eli Lilly and Company $2,182.77 04/23/2025 Non-covered Recipient Entity
INTERSPOND LLC
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY3541860 COMPARED TO PLACEBO IN SLOWING THE OCCURRENCE OF NEW T1 GADOLINIUM-ENHANCING LESIONS IN ADULT PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1187882182
Principal investigator 1 EMD Serono, Inc. $300.00 04/09/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118105
Principal investigator 1 EMD Serono, Inc. $1,280.00 04/09/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118109
Principal investigator 1 EMD Serono, Inc. $330.00 04/09/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118113
Recipient Eli Lilly and Company $48.00 04/08/2025 Covered Recipient Physician AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY3541860 COMPARED TO PLACEBO IN SLOWING THE OCCURRENCE OF NEW T1 GADOLINIUM-ENHANCING LESIONS IN ADULT PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1187871083
Principal investigator 1 GENZYME CORPORATION $5,362.00 04/07/2025 Non-covered Recipient Entity
Interspond LLC
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226147888
Principal investigator 1 ABBVIE INC. $10,341.80 04/03/2025 Non-covered Recipient Entity
PREMIER NEUROLOGY PC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202473838
Principal investigator 1 GENZYME CORPORATION $4,000.00 04/02/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226147867
Principal investigator 1 TG Therapeutics, Inc. $6,000.00 04/01/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198949
Principal investigator 1 TG Therapeutics, Inc. $52,340.72 04/01/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198957
Principal investigator 1 TG Therapeutics, Inc. $5,070.34 04/01/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199005
Principal investigator 1 TG Therapeutics, Inc. $12,725.00 03/31/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198955
Principal investigator 1 EMD Serono, Inc. $770.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118117
Principal investigator 1 Eli Lilly and Company $7,400.00 03/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LY3541860 COMPARED TO PLACEBO IN SLOWING THE OCCURRENCE OF NEW T1 GADOLINIUM-ENHANCING LESIONS IN ADULT PARTICIPANTS WITH RELAPSING MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1187883234
Principal investigator 1 EMD Serono, Inc. $1,500.00 03/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118373
Principal investigator 1 EMD Serono, Inc. $2,452.00 03/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118377
Principal investigator 1 EMD Serono, Inc. $1,000.00 03/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118381
Principal investigator 1 ABBVIE INC. $4,922.40 03/07/2025 Non-covered Recipient Entity
PREMIER NEUROLOGY PC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202459596
Principal investigator 1 PFIZER INC. $392.22 03/06/2025 Non-covered Recipient Entity
Interspond LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228767017
Principal investigator 1 TG Therapeutics, Inc. $14,061.00 02/28/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198953
Principal investigator 1 GENZYME CORPORATION $1,537.50 02/24/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226147856
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,722.44 02/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190299619
Principal investigator 1 TG Therapeutics, Inc. $4,269.76 02/17/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199001
Principal investigator 1 Eli Lilly and Company $900.00 02/12/2025 Non-covered Recipient Entity
INTERSPOND LLC
PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) No dispute reported 06/30/2026 1187882090
Principal investigator 1 ABBVIE INC. $11,177.60 02/06/2025 Non-covered Recipient Entity
PREMIER NEUROLOGY PC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202449606
Principal investigator 1 TG Therapeutics, Inc. $10,870.00 01/31/2025 Non-covered Recipient Entity
Premier Neurology
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226198951
Principal investigator 1 EMD Serono, Inc. $500.00 01/28/2025 Non-covered Recipient Entity
INTERSPOND LLC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118385
Principal investigator 1 Novartis Pharmaceuticals Corporation $37,827.00 01/28/2025 Non-covered Recipient Entity
INTERSPOND LLC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190299603
Principal investigator 1 GENZYME CORPORATION $11,747.00 01/21/2025 Non-covered Recipient Entity
Interspond LLC
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226147978
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,737.68 01/09/2025 Non-covered Recipient Entity
PREMIER NEUROLOGY
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190305541
Principal investigator 1 Novartis Pharmaceuticals Corporation $245,037.84 01/01/2025 Non-covered Recipient Entity
PREMIER NEUROLOGY
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190305545